Oryzon Genomics SA (MC:ORY) — Stock Price

€2.90 EUR
▼ -0.27% today

Oryzon Genomics SA (MC:ORY) is currently trading at €2.90 EUR, down 0.27% today. Over the past 52 weeks, shares have ranged between €2.57 and €3.82. This page tracks Oryzon Genomics SA's live share price on the MC exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see ORY market cap overview.

Oryzon Genomics SA (ORY) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Oryzon Genomics SA's daily closing share price and trading volume on the MC exchange over the past year, giving a clear view of recent price momentum and liquidity.

Oryzon Genomics SA Income Statement — Revenue, Profit & Earnings by Year

Oryzon Genomics SA's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue €0.00 €7.36 Million €14.19 Million €15.70 Million €10.62 Million
Cost of Revenue €133.91K €302.19K €243.70K €-15.23 Million €745.98K
Gross Profit €-133.91K €7.06 Million €13.95 Million €15.23 Million €9.87 Million
Research & Development €12.60 Million €6.24 Million €6.63 Million €7.35 Million
SG&A €17.62 Million €13.07 Million
Total Operating Expenses €6.29 Million €11.48 Million €18.50 Million €20.72 Million €16.88 Million
Operating Income €-6.42 Million €-4.42 Million €-4.55 Million €-5.49 Million €-7.01 Million
EBITDA €-6.29 Million €-4.43 Million €-4.43 Million €-5.35 Million €-6.88 Million
EBIT €-6.42 Million €-4.58 Million €-4.56 Million €-5.50 Million €-7.02 Million
Interest Expense €608.34K €1.23 Million €1.89 Million €1.12 Million €455.57K
Income Before Tax €-5.60 Million €-5.57 Million €-6.10 Million €-6.56 Million €-7.18 Million
Income Tax Expense €-2.99 Million €-1.91 Million €-2.75 Million €-2.33 Million €-2.49 Million
Net Income €-2.61 Million €-3.67 Million €-3.35 Million €-4.23 Million €-4.69 Million

Oryzon Genomics SA Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Oryzon Genomics SA's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets €144.52 Million €108.72 Million €106.90 Million €103.70 Million €95.38 Million
Total Current Assets €30.67 Million €8.75 Million €14.28 Million €25.16 Million €32.61 Million
Cash & Equivalents
Short-term Investments €14.58K
Net Receivables €2.24 Million €1.44 Million €646.97K €1.00 Million €1.29 Million
Inventory €3.73K €2.98K €6.03K €9.80K €103.80K
Property, Plant & Equipment €611.42K €682.42K
Goodwill
Total Liabilities €26.68 Million €21.67 Million €25.13 Million €31.13 Million €24.12 Million
Total Current Liabilities €15.77 Million €11.74 Million €16.41 Million €18.73 Million €8.67 Million
Long-term Debt €3.07 Million €3.22 Million €3.39 Million €6.98 Million €10.35 Million
Net Debt €-16.41 Million €10.59 Million €1.43 Million €-3.88 Million €-14.95 Million
Total Stockholder Equity €105.45 Million €87.04 Million €81.77 Million €72.57 Million €71.26 Million
Retained Earnings €-20.81 Million €-19.29 Million €-15.67 Million €-12.27 Million €-8.04 Million

Oryzon Genomics SA Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Oryzon Genomics SA generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow €-2.36 Million €-5.69 Million €-574.96K €-1.85 Million €-3.63 Million
Capital Expenditures €59.40K €7.71 Million €14.50 Million €14.27 Million €11.76 Million
Free Cash Flow €-2.42 Million €-13.40 Million €-15.08 Million €-16.12 Million €-15.39 Million
Investing Cash Flow €-11.04 Million €-7.81 Million €-14.50 Million €-14.27 Million €-11.72 Million
Financing Cash Flow €36.13 Million €6.87 Million €6.02 Million €8.71 Million €4.12 Million
Dividends Paid
Stock-Based Compensation
Depreciation €133.91K €147.75K €152.88K €178.73K €144.33K
Change in Cash €22.74 Million €-6.64 Million €-9.06 Million €-7.41 Million €-10.88 Million

Oryzon Genomics SA Earnings History — EPS Actual vs. Analyst Estimates

Track Oryzon Genomics SA's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Feb 27, 2026 -0.02 -0.03 +33.33%
Nov 07, 2025 0.01 -0.03 +133.33%
Jul 30, 2025 0.00 -0.03 +104.33%
May 12, 2025 -0.03 -0.01 -200.00%
Feb 27, 2025 -0.02 -0.01 -100.00%
Oct 24, 2024 -0.02 -0.02 +0.00%
Jul 31, 2024 0.00 -0.01 +117.00%
May 06, 2024 -0.02 -0.03 +33.33%